IO Biotech Files 10-Q: EIB Loan Facility and Stock Activity
Ticker: IOBT · Form: 10-Q · Filed: May 14, 2025 · CIK: 1865494
| Field | Detail |
|---|---|
| Company | Io Biotech, Inc. (IOBT) |
| Form Type | 10-Q |
| Filed Date | May 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financing, debt, stock
TL;DR
IO Biotech 10-Q filed: EIB loan facility active, stock/warrant activity noted. Looks like they're still funded.
AI Summary
IO Biotech, Inc. filed its 10-Q for the period ending March 31, 2025. The company's financial statements reflect activities related to its common stock, warrants, and a loan facility with the European Investment Bank (EIB). Key financial events include the issuance of common stock and warrants, and the establishment of credit facilities, such as the Two Thousand Twenty-Four EIB Term Loan Facility.
Why It Matters
This filing provides insight into IO Biotech's financial health and ongoing financing activities, particularly its relationship with the European Investment Bank, which is crucial for its operational and development funding.
Risk Assessment
Risk Level: medium — The company's reliance on debt financing, such as the EIB loan facility, and the nature of its stock and warrant issuances suggest potential financial risks and dilution.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the financial data covers the first quarter of 2025.)
- 001-41008 — SEC File Number (Identifies the specific SEC filing for IO Biotech.)
Key Players & Entities
- IO Biotech, Inc. (company) — Filer of the 10-Q
- European Investment Bank (company) — Lender for the loan facility
- Two Thousand Twenty-Four EIB Term Loan Facility (dollar_amount) — Specific credit facility mentioned
- 20250331 (date) — End of the reporting period
FAQ
What is the current status of IO Biotech's loan facility with the European Investment Bank as of March 31, 2025?
The filing mentions the 'TwoThousandTwentyFourEIBTermLoanFacility' and 'CreditFacilityTrancheOne' and 'CreditFacilityTrancheB', indicating the facility is active and has specific tranches.
What significant stock or warrant activities occurred during the reporting period?
The filing references 'us-gaap:CommonStockMember' and 'us-gaap:WarrantMember' for the period of January 1, 2025, to March 31, 2025, suggesting related transactions.
What was the company's fiscal year end?
The fiscal year end for IO Biotech, Inc. is December 31.
Where is IO Biotech, Inc. headquartered?
IO Biotech, Inc.'s business and mailing address is listed as Ole Maaloes Veh 3, Copenhagen, G7, 2200.
What is the SIC code for IO Biotech, Inc.?
The Standard Industrial Classification code for IO Biotech, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 14, 2025 regarding IO Biotech, Inc. (IOBT).